Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

Orion Group Financial Statement Release January–December 2025

View original at globenewswire.com
Orion Group Financial Statement Release January–December 2025 ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October–December 2024: 434.4) million Operating…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The outlook for 2026 does not include any material milestone payments

    80% confidence

  • Sales and marketing expenses are expected to increase in 2026

    80% confidence

  • R&D costs in 2026 will increase from 2025

    80% confidence

  • Animal Health business division is anticipated to grow slightly in 2026

    80% confidence

  • Nubeqa has consistently exceeded expectations, and Orion's annual Nubeqa net sales have the potential to exceed EUR 1 billion by the end of the current decade

    80% confidence

  • Total capital expenditure in 2026 is not expected to have significant changes compared to 2025

    80% confidence

  • Nubeqa royalties and product sales booked by Orion will increase clearly in 2026

    80% confidence

  • Expecting another very strong year in 2026 with continued determined work to build well-being and Orion's future

    80% confidence

  • Orion aims to expand the ODM-212 phase 2 program during 2026

    80% confidence

  • ODM-212 has a lot of potential with its mode of action in various indications beyond rare cancers

    80% confidence

  • Orion delivered a very strong performance in 2025 with solid financial results and clear progress in executing strategy

    80% confidence

  • Branded Products business division is estimated to grow in 2026, driven by Respiratory therapy area and Easyhaler portfolio

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com